Gene Delivery Using Viral Vectors - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 258

[18] Mittereder N, Yei S, Bachurski C, Cuppoletti J, Whitsett JA, Tolstoshev P, et al.
Evaluation of the efficacy and safety of in vitro , adenovirus-mediated transfer of the
human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther
1994;5:717-29.
[19] Graham FL, Prevec L. Methods for construction of denovirus vectors. Mol Biotechnol
1995;3:207-20.
[20] Graham FL. Covalently closed circles of human adenovirus DNA are infectious. EMBO
J 1984;3:2917-22.
[21] Ng P, Parks RJ, Cummings DT, Evelegh CM, Graham FL. An enhanced system for
construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther
2000;11:693-9.
[22] He TC, Zhou S, da Costa L,T, Yu J, Kinzler KW, Vogelstein B. A simplified system for
generating recombinant adenoviruses. Proc Natl Acad Sci U.S.A. 1998;95:2509-14.
[23] Danthinne X, Werth E. New tools for the generation of E1- and/or E3-substituted adeno-
viral vectors. Gene Ther 2000;7:80-7.
[24] Rainov NG, Xandra OB, Christof MK. Review article. Routes of vector application for
brain tumor gene therapy. Gene Ther Mol Biol 1999;3:1-14.
[25] Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, et al. Limination of both
E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene
therapy. J Virol 1996;70:4173-8.
[26] Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line
and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol
1996;70:7030-38.
[27] Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and
characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.
J Virol 1998;72:926-33.
[28] Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, Mourot B, et al. In vitro and in vivo
biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol
1998;72:2022-32.
[29] Zhou H, Beaudet A. A new vector system with inducible cell line E2T for production of
safer and higher titer adenoviral vectors. Virology 2000;275:348-57.
[30] Shenk T, et al. Adenoviridae: the viruses and their replication. In: Knipe DM, Howley
PM, Fields BN, editors. Fields virology, II. Philadelphia, PA: Lippincott Williams &
Wilkins; 2001:2265-300.
[31] Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracy-
cline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-51.
[32] Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by
expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
[33] Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for
liver-directed gene therapy. J Virol 1996;70:8934-43.
[34] Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, et al. Long-term gene
delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses.
J Virol 1997;71:4626-37.
[35] Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, et al. A pilot study of in
vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarba-
mylase deficiency. Hum Gene Ther 2002;13:163-75.
[36] Amalfitano A. Next-generation adenoviral vectors: new and improved. Gene Ther
1999;6:1643-5.
[37] Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, prepagation, and partial purification
of a helper virus dependent adenovirus vector. Proc Natl Acad Sci U.S.A. 1995;92:3854-8.